resiquimod has been researched along with Carcinoma, Pancreatic Ductal in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belt, BA; Garrett-Larsen, J; Gerber, SA; Han, BJ; Johnston, CJ; Linehan, DC; Lord, EM; Mills, BN; Murphy, JD; Qin, SS; Uccello, TP; Vrooman, TG; Ye, J | 1 |
| Angeles Ramos, DM; Burfeind, KG; Coussens, LM; Levasseur, PR; Liudahl, SM; Marks, DL; Maurer, HC; Michaelis, KA; Morgan, TK; Norgard, MA; Olive, KP; Olson, B; Pelz, KR; Sivagnanam, S; Zhu, X | 1 |
2 other study(ies) available for resiquimod and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
Topics: Adjuvants, Immunologic; Animals; Antigens, Neoplasm; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Disease Models, Animal; Humans; Imidazoles; Liver Neoplasms; Mice; Pancreatic Neoplasms; Radiosurgery; Toll-Like Receptor 7; Toll-Like Receptor 8; Tumor Microenvironment | 2022 |
The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer.
Topics: Animals; Body Weight; Cachexia; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Eating; Gene Expression; Humans; Imidazoles; Locomotion; Mice; Mice, Knockout; Pancreatic Intraductal Neoplasms; Pancreatic Neoplasms; Sequence Analysis, RNA; Survival Rate; Toll-Like Receptor 7; Toll-Like Receptor 8; Tumor Burden; Tumor Microenvironment | 2019 |